<DOC>
	<DOC>NCT00358878</DOC>
	<brief_summary>Primary:To evaluate the efficacy of satavaptan on top of conventional treatment in the treatment of clinically evident ascites in participants with cirrhosis of the liver. Secondary:To evaluate the tolerability and safety of satavaptan over a 52-week treatment period in participants with cirrhosis of the liver and ascites. The one-year double blind placebo controlled period is extended up to 2 years in a long term safety study (PASCCAL-2).</brief_summary>
	<brief_title>Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Satavaptan</mesh_term>
	<criteria>Participants with cirrhosis of the liver Participants with clinically evident ascites primarily managed by diet and/or diuretics Stable treatment of ascites for at least the previous 2 weeks without paracentesis Participants having undergone no more than one therapeutic paracentesis in the previous 6 months. Participants with an existing functional transjugular intrahepatic portosystemic shunt (TIPS) or other shunt Known hepatocellular carcinoma Participants with ascites of cardiac origin or due to peritoneal infection (e.g. tuberculosis) or peritoneal carcinoma Participants previously exposed to satavaptan in the past 12 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Ascites</keyword>
	<keyword>Liver Cirrhosis</keyword>
</DOC>